Claim check · Effectiveness
BPC-157 and tendon healing
Claim (representative wording, not a quotation): BPC-157 heals torn tendons.
Plain-English answer
In animals and cells, BPC-157 has been reported to help tendon healing, with mixed results in the most recent rat study. In the sources and registries WPF searched, no completed controlled human study of tendon healing was found, so a claim that it heals human tendons is not supported.
Verdict: Overstated. Part of the claim is supported, but the claim says more than the sources show: a wider population, a stronger outcome, a human result from animal work, or a certainty the design cannot give.
Scope
- Population or organism
- Rats and cultured rat tendon cells (almost all of the evidence); humans (almost none)
- Study design
- Animal experiments, cell experiments, a systematic review of them, one uncontrolled human case series of knee pain, and registered human trials without posted results
- Boundary
- Tendon healing only. This check does not assess muscle, gut or pain claims, and does not assess safety. Its conclusion is limited to the sources and registries named under "Where WPF looked for missing evidence".
Strongest evidence
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study (J Dis Relat Surg, 2026; 37(3); PMID 42542926; DOI 10.52312/jdrs.2026.2951) (Peer-reviewed paper)
Population or organism: 32 male Sprague-Dawley rats: 8 rats per group in 4 groups (control, BPC-157, TB-500, BPC-157 plus TB-500); 4 tendons per group analysed biomechanically and 4 tendons per group analysed histologically, so n = 4 per group for each type of analysis
Design: Randomized (simple randomization) animal experiment reported to ARRIVE guidelines: Achilles tendon transection with primary Kessler repair, then daily intraperitoneal injection for 30 postoperative days (the abstract says four weeks); outcomes at day 30; histology scored by a blinded pathologist, biomechanical specimens coded; treatment could not be blinded; the authors call it exploratory
Where in the source: Full text read on the journal's open-access site (jointdrs.org/full-text/1851) on 2026-11-15. Patients and Methods, first paragraph, and the paragraph beginning "On day 30", and Figure 1 caption: 32 rats, n = 8 per group, 4 tendons per group to biomechanical testing and 4 to histological, histochemical and immunohistochemical evaluation (effective n = 4 per group for all non-biomechanical analyses). Results, Figure 2 (maximum load to failure, median [IQR], N; n = 4 per group): control 26.91 [26.12-30.44], BPC-157 37.16 [33.01-46.45], TB-500 37.41 [37.10-47.82], combination 34.54 [33.02-36.24]; Kruskal-Wallis p = 0.0165; only TB-500 versus control significant (Dunn adjusted p = 0.0406; BPC-157 versus control 0.389). Table I, row Total Bonar (0-12), median [IQR]: control 9.5 [7.5-10.75], BPC-157 5.0 [4.25-5.75], TB-500 4.0 [4.0-4.75], combination 4.5 [4.25-5.75]; overall p = 0.005; versus control: BPC-157 p = 0.273, TB-500 p = 0.016, combination p = 0.103. Table II, row Total Movin (0-24): control 18.0 [14.0-19.75], BPC-157 9.5 [8.25-10.75], TB-500 8.0 [7.25-8.75], combination 8.0 [8.0-8.75]; overall p = 0.002; versus control: BPC-157 p = 0.601, TB-500 p = 0.017, combination p = 0.040. So on the total scores only TB-500 (Bonar, Movin and load to failure) and the combination (Movin) differed significantly from control; BPC-157 alone did not.
BPC 157 promotes tendon outgrowth, cell survival and migration (J Appl Physiol, 2011; PMID 21030672) (Peer-reviewed paper)
Population or organism: Rat Achilles tendon explants and cultured rat tendon fibroblasts
Design: Cell and tissue experiments (in vitro / ex vivo)
Where in the source: Abstract, Results: accelerated tendon-explant outgrowth, increased fibroblast survival under H2O2 stress and dose-dependent migration; no direct effect on proliferation.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (HSS J, 2025; PMID 40756949; PMC12313605) (Systematic review)
Population or organism: 36 included studies, 35 preclinical and 1 clinical (the clinical one is the knee-pain case series below)
Design: Systematic review of English-language literature in PubMed, Cochrane and Embase from inception to 3 June 2024; screening in 3 phases by 2 reviewers; the review itself describes the evidence as level IV and V
Where in the source: Abstract, Results: 544 articles identified, 36 included. The one clinical study is described as a retrospective study of intra-articular injection for chronic knee pain: "7 of 12 patients reported relief for >6 months" (Results, text beginning "Only 1 clinical study could be identified", and Table 2, row Lee et al 2021: 7 of 12 patients reported subjective improvement in symptoms for more than 6 months after BPC-157 alone). It is about knee pain, not tendon healing.
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (Altern Ther Health Med, 2021; 27(4):8-13; PMID 34324435) (Peer-reviewed paper)
Population or organism: Adults with knee pain from several causes treated at one clinic: 17 patients in the chart review, 16 reached by telephone
Design: Retrospective, uncontrolled case series (chart review plus telephone follow-up). No comparison group. Patients rated their own pain and the benefit; no specific tool measured function, quality of life, stiffness or daily activities. It assessed knee pain, not tendon healing
Where in the source: Abstract, Results: of the 16 patients, 12 received BPC-157 alone and "11 of the 12 patients (91.6%) had significant improvement in knee pain" (patient-reported, any duration, different from the review's "7 of 12 relief for more than 6 months"); the other 4 received BPC-157 with thymosin beta-4 (75% improved); overall 14 of 16. Abstract only: WPF did not read the full text, so how the series' 11 of 12 and the review's 7 of 12 relate within the full paper was not checked.
NCT07803250: BPC-157 after arthroscopic rotator cuff repair (University of Arkansas) (Registry record)
Population or organism: Planned 30 adults having rotator cuff repair
Design: Randomized, quadruple-masked phase 1 pilot; status not yet recruiting; start 2027-01-01 (registry verified 2026-09)
Where in the source: Registry record, rechecked 2026-11-15: primary outcome shoulder strength at baseline, 12 weeks and 5 months; the summary states a tendon-healing aim; no results posted. The record describes the comparison arm as normal saline in one field and as no treatment in another.
NCT07437547: BPC 157 for acute hamstring muscle strain (Hudson Biotech) (Registry record)
Population or organism: Planned 120 participants with an acute grade II hamstring muscle strain
Design: Randomized, quadruple-masked phase 2; status recruiting (registry verified 2026-02)
Where in the source: Registry record, rechecked 2026-11-15: primary outcomes time to return to sport and MRI injury volume at 14 days; a muscle injury, not a tendon outcome; no results posted.
NCT02637284: PCO-02 (Bepecin) safety and pharmacokinetics (PharmaCotherapia) (Registry record)
Population or organism: Healthy volunteers
Design: Randomized phase 1 safety and pharmacokinetics; status unknown, registry last verified 2015-10
Where in the source: Registry record, rechecked 2026-11-15: primary outcome adverse events; no tendon outcome; no results posted.
NCT07752381: peptide gummies containing BPC-157, markers of inflammation and recovery (Parlay Wellness) (Registry record)
Population or organism: Planned 40 physically active adults
Design: Single-arm oral supplement study; status completed (registry verified 2026-08)
Where in the source: Registry record, rechecked 2026-11-15: primary outcomes blood inflammation markers and self-reported swelling; not a tendon outcome; no results posted.
What remains uncertain
- Most of the animal literature comes from a small number of research groups, and WPF did not assess independence or risk of bias in each study.
- The 2026 rat study had n = 4 per group for each type of analysis and is described by its authors as exploratory. It found a significant effect for TB-500 but not for BPC-157 alone on the total tendon scores, so even the animal result is not uniform.
- Dose, route and timing in animals (intraperitoneal injection daily for 30 days) do not map to any human use.
- WPF read the full text of the 2026 rat study (Methods, Figures 1 and 2, Tables I and II) but, for the other studies, the abstract only, so risk of bias within those studies is not assessed here.
- The knee-pain case series has no control group and relies on patients' own reports: its 11 of 12 and the review's 7 of 12 describe different outcomes and are not evidence about tendons.
What would change the answer
- A completed, randomized, controlled human trial with a tendon-healing outcome (function, imaging or re-rupture) and posted or published results.
- Independent replication of the rat result by a group unconnected to the original investigators.
Exact gaps
- In the sources and registries WPF searched, no human tendon-healing result was found. Of the four registrations, only NCT07803250 (rotator cuff repair, not yet recruiting) is a controlled trial in tendon repair; NCT07437547 is a muscle-strain trial, NCT02637284 a phase 1 safety study of unknown status and NCT07752381 a completed supplement study of inflammation markers. None has posted results.
- Not read: the full text of the animal studies other than the 2026 rat study, and the full text of the knee-pain case series, so effect sizes and risk of bias in them are not assessed.
Where WPF looked for missing evidence
Searched on 2026-11-15 in: PubMed (NCBI E-utilities); ClinicalTrials.gov API v2.
- PubMed: BPC-157[tiab] OR "BPC 157"[tiab] OR "body protection compound"[tiab] -> 230 records
- PubMed: (BPC-157 OR "BPC 157") AND (tendon OR Achilles OR tendinopathy) in title/abstract -> 29 records
- PubMed: (BPC-157 OR "BPC 157") AND (randomized[tiab] OR "clinical trial"[pt]) -> 3 records, none a human trial of BPC-157 (two reviews and one rat study)
- ClinicalTrials.gov: query.term=BPC-157 -> 4 registrations; query.intr=BPC-157 -> 4 interventional registrations
Found: No completed human trial with a tendon outcome. The same four registrations matched on 2026-11-15 as on 2026-11-14: NCT07803250 (rotator cuff repair, phase 1, not yet recruiting), NCT07437547 (acute hamstring muscle strain, phase 2, recruiting), NCT02637284 (phase 1 safety and pharmacokinetics, status unknown, last verified 2015-10) and NCT07752381 (a supplement-gummy trial of inflammation markers, completed). None has posted results. The only human clinical study in the 2025 systematic review is an uncontrolled knee-pain case series.
Not searched: Embase and Cochrane directly (the 2025 systematic review searched them to 3 June 2024); Non-English literature beyond PubMed's indexing; Conference abstracts, theses and unregistered clinic data.
Not finding evidence in these searches is not proof that none exists.
Date checked and review status
Checked: · version 1.6.0
Review status: AI-assisted source verification. Human review: none recorded. Human review is pending and has not happened.
Related pages
Profiles: /directory/bpc-157
Cite this check
The citation names the version and an address that keeps returning what was checked, even after a newer version is published.
BPC-157 and tendon healing: In animals and cells, BPC-157 has been reported to help tendon healing, with mixed results in the most recent rat study. In the sources and registries WPF searched, no completed controlled human study of tendon healing was found, so a claim that it heals human tendons is not supported. Verdict: Overstated. Cited from World Peptide Foundation, Peptide Claims & Evidence, version 1.6.0, claim bpc-157-tendon-healing, checked 2026-11-15. AI-assisted source verification; human review none recorded.
Page:
https://www.worldpeptidefoundation.org/research/check/bpc-157-tendon-healing
Versioned record:
https://www.worldpeptidefoundation.org/api/research/claims/bpc-157-tendon-healing?version=1.6.0
Versioned record: /api/research/claims/bpc-157-tendon-healing?version=1.6.0